
GT20029 Will Replace Finasteride For Hair Loss
https://en.kintor.com.cn/news_details/1803365125008502784.html
GT20029 has a real chance of replacing finasteride for many people if larger trials confirm the early data.
Unlike finasteride or dutasteride, it does not lower DHT systemically. It is a topical PROTAC designed to bind the androgen receptor, recruit an E3 ubiquitin ligase, and send that receptor to the proteasome for degradation. So instead of just lowering DHT, the goal is to reduce the receptor DHT uses inside the follicle environment.
This could make it a serious option for people who cannot tolerate finasteride, are worried about systemic hormone changes, or want a more targeted topical approach. And obviously it’s stackable with fin and dut.
https://en.kintor.com.cn/news_details/1803365151294205952.html
https://en.kintor.com.cn/news_details/1803365146143600640.html
The safety data is also promising. In both the China and U.S. Phase 1 studies, systemic exposure was extremely low, even after repeated dosing. That matters because the entire appeal of GT20029 is local scalp activity without meaningful systemic exposure. China phase 2 also showed low to zero systemic exposure.
https://pubmed.ncbi.nlm.nih.gov/41328006/
Where it comes to results, The China Phase 2 AGA data is promising.
The study tested 180 Chinese men across six groups: 0.5% once daily, 1.0% once daily, once-daily placebo, 0.5% twice weekly, 1.0% twice weekly, and twice-weekly placebo.
All GT20029 groups improved hair counts, but only 0.5% once daily and 1.0% twice weekly clearly beat their matching placebo groups. The 1.0% twice-weekly arm also improved hair width.
Now this could seem odd because you would expect 1.0% once daily to clearly outperform 0.5% once daily, but it did not. Instead, 1.0% twice weekly looked like one of the stronger arms. However the 1.0% once daily had started at a lower baseline hair count in the group than its placebo so perhaps that group has more severe AGA subjects which made GT underperform (especially with how small the groups are).
The mechanism of GT has a lot of promise. If larger and longer trials keep showing low systemic exposure and meaningful hair growth, then yes, I think it probably replaces finasteride for many people. It could also be stacked with finasteride or dutasteride because lowering DHT and degrading the androgen receptor are not the same mechanism.
https://pubmed.ncbi.nlm.nih.gov/39884271/
https://www.nature.com/articles/s41467-026-70153-4
Now, there is the recent GPR133 paper that’s making people think that outside of lowering scalp dht, there’s nothing effective enough to help slow or reverse hair loss like fin and dut.
In this paper, the authors suggest DHT can activate GPR133 in the connective tissue sheath, causing sheath contraction, Piezo-type mechanosensitive ion channel component 1 activation, progenitor-cell stress, and reduced follicle growth. So in other words, DHT doesn’t need the Androgen Receptor to cause stress to the hair follicle. It may restrict its growth via GPR133 receptor. So this could mean drugs like GT are useless.
https://www.nature.com/articles/s41467-026-70153-4
However I have an issue with the paper as there are some inconsistencies that make me write off GPR being a major issue for Aga. Much of the work in the paper comes from isolated follicles, ex vivo systems, single-cell/spatial transcriptomics, and humanized mouse models. These are useful tools, but they do not prove that GPR133 inhibition restores AGA in a normal human scalp environment.
https://www.nature.com/articles/s41467-026-70153-4
The biggest issue is the dermal papilla data. The authors found that dermal papilla subcluster percentage and distribution were mostly comparable between healthy, non-balding, and balding follicles. That is strange because the dermal papilla is supposed to be one of the main structures disrupted in androgenetic alopecia. They typically reduce in number and size.
https://www.nature.com/articles/s41467-026-70153-4
https://pubmed.ncbi.nlm.nih.gov/35033537/
Even the authors acknowledge the issue. They note that AGA is usually understood through dermal papilla miniaturization, reduced dermal papilla volume, reduced cell number, and loss of inductive capacity. They also cite their own prior work showing androgen receptor upregulation in dermal papilla cells, reduction in size and density of these cells along with their signaling activity, and more comparable to their recent study they do note vascular regression around the dermal papilla. They admit their newer single-cell analysis did not show obvious dermal papilla changes beyond reduced angiogenesis signaling and that’s a major issue and contradiction of the literature and pathway of AGA.
https://pubmed.ncbi.nlm.nih.gov/35033537/
That is not a small detail. if the newer GPR133 paper finds balding and non-balding dermal papilla subclusters looking mostly similar, that discrepancy needs to be explained before we oversell the significance of GPR133 and DHT on the hair follicle.
https://www.nature.com/articles/s41467-026-70153-4
To me, this suggests the GPR133 paper is capturing one slice of AGA biology, not the whole disease. The study focused heavily on early miniaturizing anagen follicles from the frontal hairline edge, with a limited number of male samples. That is useful mechanistic data, but not enough to claim this pathway explains AGA broadly across the whole scalp.
That is why GT20029 still makes sense. If androgen receptor activity in the dermal papilla region is one of the main upstream problems, then locally degrading the androgen receptor remains a direct strategy. GPR133 may add another layer to DHT biology, but it does not replace the classic androgen receptor/dermal papilla pathway.